Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) on Tuesday, soared 1.51% from the previous trading day, before settling in for the closing price of $11.94. Within the past 52 weeks, CNTA’s price has moved between $8.46 and $19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 37.42%. With a float of $84.83 million, this company’s outstanding shares have now reached $133.55 million.
Considering the fact that the conglomerate employs 77 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Centessa Pharmaceuticals plc ADR (CNTA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Centessa Pharmaceuticals plc ADR is 36.48%, while institutional ownership is 57.67%. The most recent insider transaction that took place on May 27 ’25, was worth 128,225. In this transaction Chief Business Officer of this company sold 10,000 shares at a rate of $12.82, taking the stock ownership to the 122,279 shares. Before that another transaction happened on May 27 ’25, when Company’s Officer proposed sale 10,000 for $12.82, making the entire transaction worth $128,225.
Centessa Pharmaceuticals plc ADR (CNTA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 37.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.99% during the next five years compared to -210.04% drop over the previous five years of trading.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Centessa Pharmaceuticals plc ADR (CNTA) is currently performing well based on its current performance indicators. A quick ratio of 14.37 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 107.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.48 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Compared to the last year’s volume of 0.91 million, its volume of 1.7 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 36.10%. Additionally, its Average True Range was 0.79.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 26.55%, which indicates a significant decrease from 40.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.95% in the past 14 days, which was lower than the 62.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.66, while its 200-day Moving Average is $15.30.
